GSK leads European charge into Yankee land of plenty
The depth of the US corporate bond market and its razor-sharp appetite for high grade credit were vividly apparent this week as GlaxoSmithKline issued its first bond for three years, in an apparently effortless $5bn three tranche sale.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: